Dr Reddy's Laboratories launches Icosapent Ethyl Capsules in US Market

Dr. Reddy’s Icosapent Ethyl is available in 1 gram capsules in bottle count size of 120’s count.

Jun 22, 2021 09:06 IST India Infoline News Service

Dr Reddys Laboratories
Dr. Reddy’s Laboratories Ltd on Tuesday has announced the launch of Icosapent Ethyl Capsules, 1 gram approved by the U.S. Food and Drug Administration (USFDA).

Dr. Reddy’s Icosapent Ethyl Capsules, 1 gram is approved as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

The effect of Icosapent Ethyl Capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

Dr. Reddy’s Icosapent Ethyl is available in 1 gram capsules in bottle count size of 120’s count.

Informations regarding Icosapent Ethyl are:
  • Icosapent Ethyl is associated with an increased risk of heart arrhythmias (atrial fibrillation or atrial flutter) requiring hospitalization
  • Potential allergic reactions in patients with fish and/or shellfish allergy
  • Please discontinue and seek medical attention if you experience any reactions
  • Icosapent Ethyl is associated with an increased risk of bleeding. The incidence of bleeding is greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin, as mentioned by the pharma company.
According to the company, Dr. Reddy’s Icosapent Ethyl Capsules is not approved as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease.

On Tuesday early morning trade, Dr Reddy's was trading at Rs5292.80 per share higher by 0.25% on Sensex.

Related Story

Open Free Demat Account (Rs699)